Authors
Latest:
CDMOs are Exploring Risk-Sharing for Resilient Growth in a BANI WorldKey industry trends and how the relationships between companies and CDMOs are evolving to better meet the challenges of a BANI world.
Latest:
The Healthcare System is Changing—So How Should We Respond?What pharma needs to do to keep up with the rise in value-based care.
Latest:
Cracking Down on Speaker ProgramsWith heightened government scrutiny on educational forums, biopharma manufacturers need a sound framework that demonstrates they are following best practices.
Latest:
EU Medical Device Supply Chains and Trade Agreements: The COVID-19 ResponseAndrew Hood and Cliodhna McDonough look at the key issues necessary to support business and the community in developing a long-term and sustainable response to the challenges highlighted by COVID-19.
Latest:
How Market Access Can Determine Commercial SuccessUsing market access data from day one of your drug development and commercialization journey puts your brand in the best position to succeed at launch.
Latest:
How to Lead and Succeed in the Biosimilars SpaceKey traits needed by leaders looking to grow their organizations in the biosimilars market.
Latest:
Shedding Light on Global Pharmaceutical Supply ChainsIncrease in new treatments also brings increase in logistical challenges for pharma.
Latest:
Patients and Data Disrupt the Life Sciences IndustryDelivering better patient outcomes hinges on innovation and adaptability.
Latest:
The Promise of Agentic AI to Cut Through HCP Marketing OverwhelmPrioritizing deeper customer insights helps life sciences marketers understand how to engage their HCP audiences effectively with the right message.
Latest:
A New Era in European Life Sciences InvestmentInvestments setting up sector for future success that could one day rival its US counterpart.
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
Latest:
New Technologies Come with New Litigation RisksCybersecurity vulnerabilities embedded in AI and machine learning pose significant litigation risks as life sciences companies move to digital technologies.
Latest:
Navigating the European Market for Medical CannabisThere is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.
Latest:
The Global Vaccine R&D Pipeline and Delivery ImplicationsThe current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.
Latest:
Eli Lilly to Construct $5 Billion Manufacturing Plant in Virginia, Expanding US Biopharma CapacityThe new Goochland County facility will serve as Lilly’s first fully integrated API and drug product site, focusing on antibody-drug conjugates, while creating thousands of jobs and strengthening domestic supply chains.
Latest:
Turning AI Pilots into Enterprise ValueThe key steps for pharma in pivoting from proof-of-concept experimenting to enterprise-scale value.
Latest:
Navigating the EU’s Joint Clinical AssessmentPathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.
Latest:
The Role of AI in Helping Clinicians Diagnose PatientsThree ways artificial intelligence can drive the necessary engagement between patients and HCPs.
Latest:
The Emergence of the Chief Value Officer in HealthcareOutlining the implications of this c-suite trend for pharma.
Latest:
The Future of Safety and Adverse Event ProcessesAddressing the increased use of technology in safety compliance processes and greater patient involvement.
Latest:
How Biopharma Can Rev Up the Analytics Engine to Boost Patient ComplianceWhile patient support providers play an important role in keeping patients on therapy, biopharma companies have a great opportunity to push analytical sophistication beyond what many of these providers currently offer.
Latest:
Partnerships Are Key to Niche Markets in BrazilForging effective partnerships with local companies is particularly important when entering Brazil’s pharma market. Sameer Kolhe reports.
Latest:
Has Pharma Given Up on Long-Term Adherence?Will the FDA ultimately step in and mandate a credible effort to eradicate the mindset that long-term adherence is not achievable?
